Zomedica recorded a net loss of approximately $16.9 million, or $0.05 per share, for the year ended December 31, 2020.

The company recorded no revenues in 2020.

Cash and cash equivalents totaled approximately $62.0 million as of December 31, 2020, compared to $0.5 million as of December 31, 2019.

The net loss resulted from R&D expenses of approximately $8.0 million, G&A expenses of approximately $6.0 million, and professional fees of approximately $2.2 million.